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Summary
Background: The b-lactam antibiotics, in combination with aminoglycosides, are among the most
widely prescribed antibiotics. However, because of extensive and unnecessary use, resistance to
these drugs continues to increase. In recent years, resistance in the Indian bacterial population has
increasedmarkedly, themajority showing complexmechanisms. Due to increased transcontinental
movement of the human population, it would be wise to know the prevalence and resistance
complexity of these strains, well in advance, in order to formulate a policy for empirical therapy.
Methods: One hundred and eighty-one isolates of Escherichia coli and 61 isolates of Klebsiella
pneumoniae obtained from 2655 non-repeat samples of pus (912) and urine (1743) were studied,
and their resistance rates and patterns were noted. The isolates were analyzed for prevalent
aminoglycoside and cephalosporin resistance phenotypes and for the presence of extended
spectrum b-lactamase (ESBL) and AmpC enzymes by spot-inoculation and modified three-dimen-
sional tests developed in our laboratory. Fourteen isolates of E. coli and six of K. pneumoniae,
resistant to all of the antibiotics tested, were selected for plasmid screening, curing, and
transconjugation experiments, and for comparative evaluation of the double disk synergy test
(DDST) and modified three-dimensional test (TDT) for detection of b-lactamases.
Results: Urinary E. coli isolates showed maximum susceptibility to amikacin (57.1%), followed by
tobramycin (38.5%) and gentamicin (31.9%). Eighteen (19.8%) isolates were susceptible to cefo-
taxime, whereas 11 (12.1%) were susceptible to ceftriaxone. The K. pneumoniae isolates from
urine samples showed maximum susceptibility to tobramycin (63.6%) followed by amikacin
(54.5%). Of the K. pneumoniae isolates, 31.8% were susceptible to cefotaxime and 13.6% were* Corresponding author. Tel.: +91 571 2720382; fax: +91 571 2721776.
E-mail address: shahidsahar@yahoo.co.in (M. Shahid).
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susceptible to ceftriaxone. A more or less similar trend of antibiotic susceptibility was noted in E. coli
and K. pneumoniae isolates frompus samples. Twenty-six (14.4%) E. coli and 15 (24.6%) K. pneumoniae
isolates were found to be ESBL-producers by NCCLS-ESBL phenotypic confirmatory test. Eighteen
(9.9%) E. coli and 19 (31.1%) K. pneumoniae isolates were found to be AmpC enzyme-producers by our
modified TDT. The simultaneous occurrence of ESBL and AmpC enzymes was noted in 7.7% and 9.8%
isolates of E. coli and K. pneumoniae, respectively.
Conclusions: The prevalence of multidrug-resistant bacterial isolates is quite high in our bacterial
population. On comparative evaluation of DDSTand TDT in resistant isolates, TDTwas found to be the
better method, detecting ESBLs in 80% of isolates compared to 15% with DDST. A 19.9-kb plasmid was
consistently present in all the screened isolates of E. coli and K. pneumoniae, and was inferred to
encode cefoxitin and tetracycline resistance based on curing and transconjugation experiments.
# 2007 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.Introduction
An increase in the emergence of multidrug-resistant bacteria
in recent years is worrying the world population. The pre-
sence of antibiotic resistance genes on bacterial plasmids has
further helped in the transmission and spread of drug resis-
tance among pathogenic bacteria.1,2 To combat antibiotic
resistance, a broad array of potent antibiotics is available to
present-day clinicians. However, growing problems with anti-
microbial drug resistance are beginning to erode our anti-
biotic armamentarium.3
The b-lactam antibiotics, in combination with aminogly-
cosides, are among the most widely prescribed antibiotics
and are important components of empirical therapy. Because
of extensive and unnecessary use in developing countries,
resistance to these drugs has become a major problem
especially after the introduction of newer broad-spectrum
cephalosporins, b-lactamase inhibitor/b-lactam antibiotics,
monobactams, and carbapenems. A major feature in the
emergence of multidrug-resistant Gram-negative bacilli is
the production of extended-spectrum b-lactamases (ESBLs)
and enzymatic modification of aminoglycosides, which are
responsible for resistance to b-lactam antibiotics and ami-
noglycosides, respectively. Plasmid-mediated ESBLs in a vari-
ety of Gram-negative bacterial species have been reported
from various developed countries;4 however, data on this
subject and the prevalent aminoglycoside and cephalosporin-
resistant phenotypes is rudimentary from Indian hospitals.
Plasmid-encoded AmpC b-lactamases are produced by
numerous pathogens.5 However, the true rate of occurrence
of AmpC enzymes has not yet been extensively studied,
especially not in Indian isolates.6 Hence, the present study
was designed to determine the resistance rates and patterns
in Escherichia coli and Klebsiella pneumoniae isolates, to
infer the prevalent resistance phenotypes, to detect the
ESBLs and AmpC b-lactamases by spot-inoculation and mod-
ified three-dimensional test, and to screen a few isolates for
R-plasmids and plasmid-mediated antibiotic resistance.
Materials and methods
Bacterial isolates
A total of 2655 non-repeat samples of pus (n = 912) and urine
(n = 1743) obtained from hospitalized patients at JawaharlalNehru Medical College and Hospital, India, during the period
from 1 May to 31 July 2003, were subjected to routine culture
and susceptibility testing. The isolates of E. coli (n = 181) and
K. pneumoniae (n = 61) were included in the study, and
resistance rates and patterns were noted.
Antibiotic susceptibility testing
Antibiotic susceptibility testing was performed according to
the method of Bauer et al.7 on Mueller—Hinton agar (HiMe-
dia, India) by using commercial antibiotic disks (HiMedia,
India). For E. coli isolates, the antibiotics used (mg/disk)
were: ampicillin (10), co-trimoxazole (trimethoprim—sulfa-
methoxazole, 1.2/23.8), tetracycline (30), amikacin (30),
gentamicin (10), tobramycin (10), ciprofloxacin (5), cefotax-
ime (30), and ceftriaxone (30). For K. pneumoniae, all the
above-mentioned antibiotics were used, except ampicillin.
Nitrofurantoin (300 mg) and norfloxacin (10 mg) were also
used for isolates from urine samples. The results were inter-
preted as per the guidelines of the National Committee for
Clinical Laboratory Standards (NCCLS).8
Determination of aminoglycoside/cephalosporin
resistance phenotypes and possible resistance
mechanisms
Aminoglycoside and cephalosporin resistance phenotypes
and resistance mechanisms were inferred by ‘interpretative
reading’.9 A range of cephalosporins and aminoglycosides
(HiMedia, India) along with some other classes of antibiotics
(HiMedia, India) were used for determination of resistance
phenotypes and to interpret the cephalosporin and amino-
glycoside resistance mechanisms.
All the isolates of E. coli and K. pneumoniae were tested
to infer aminoglycoside resistance phenotypes and possible
mechanisms of aminoglycoside resistance. The aminoglyco-
side antibiotics used (mg/disk) were: gentamicin (10), ami-
kacin (30), tobramycin (10), kanamycin (30), neomycin (30),
and netilmicin (30). Since a large panel of antibiotics is
required to infer the mechanism of cephalosporin resistance,
the isolates found to be ESBL-producers by NCCLS phenotypic
confirmatory test and AmpC-producers by three-dimensional
test (TDT), were tested to determine cephalosporin resis-
tance phenotypes and possible mechanisms of cephalosporin
resistance. The antibiotics used to detect cephalosporin
resistance phenotypes and mechanisms (mg/disk) were:
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(75), ticarcillin—clavulanate (75/10), piperacillin (100),
piperacillin—tazobactam (100/10), cephalothin (30), cefur-
oxime (30), ceftriaxone (30), cefepime (30), cefoxitin (30),
aztreonam (30), and imipenem (10).
ESBL detection by NCCLS phenotypic method
The NCCLS-ESBL phenotypic confirmatory test with ceftazi-
dime (CAZ)10 was used for all the isolates by the disk diffusion
method. Mueller—Hinton agar plates and disks containing
30 mg of CAZ, with and without 10 mg of clavulanic acid
(CA), were used. Susceptibility test results were interpreted
according to the criteria established by the NCCLS.10 A 5-
mm increase in the zone diameter of CAZ tested in combina-
tion with CA versus its zone when tested alone, was con-
sidered indicative of ESBL production. Escherichia coli ATCC
25922 and Klebsiella pneumoniae 700603 were used as con-
trol strains.
Detection of AmpC b-lactamases
All the isolates of E. coli and K. pneumoniae, irrespective of
the cefoxitin zone diameters, were screened for the pre-
sence of AmpC enzymes by spot-inoculation method as pre-
viously described.11 The screen-positive isolates were further
confirmed phenotypically for the presence of AmpC enzymes
by modified TDT as previously described.11
A limited number of isolates that were found resistant to
all of the primary screening antibiotics and not giving any
zone of inhibition (E. coli, n = 14; K. pneumoniae, n = 6),
were selected for detection of R-plasmids, curing experi-
ments, transconjugation experiments, random amplification
of polymorphic DNA (RAPD)-polymerase-chain reaction (PCR)
typing, and for comparison of ESBL detection by double disk
synergy test (DDST) and modified TDT.
Screening for R-plasmids
The selected isolates of E. coli and K. pneumoniae were
screened for R-plasmids by the alkaline lysis method of Davis
et al.,12 as adopted in our previous studies.6,13 Plasmid
samples (25 ml) were electrophoresed through 0.8% agarose
(type 1, Sigma) containing ethidium bromide (0.5 mg/ml) in
TBE buffer at 150 V, 60 mA for 3 h by the method of Portnoy
et al.14 A 1-kb ladder (Promega Corp., Madison, WI, USA) was
used as a reference molecular weight marker. Plasmid bands
were analyzed by gel documentation system (Vilber Lourmat,
France), and their respective molecular weights were calcu-
lated with the help of PhotoCaptMW Software provided with
the gel documentation system.
Curing experiments
For curing experiments, the method described by Guerry and
Colwell15 was used with slight modifications as described
elsewhere.13,16 Ethidium bromide (Sibisco Research Lab.
Ltd, India) was used as the curing agent. The minimal inhi-
bitory concentration (MIC) of ethidium bromide was deter-
mined for the bacterial isolates in trypticase soy broth (TSB),
and the highest concentration permitting growth was usedfor plasmid curing. Subcultures were initially done on trypti-
case soy agar and the colonies were tested for antibiotic
susceptibility. Concomitant loss of the antibiotic resistance
was compared with the loss of plasmid content.
Transconjugation experiments
Transconjugation experiments were done following the
method of Abigail et al.17 Mating was performed with E. coli
K12J62-2 (Frif+lac) as recipient strain. Transconjugants
were selected on MacConkey agar supplemented with rifam-
pin (2.5 mg/ml) and cefoxitin (20 mg/ml).
RAPD-PCR typing
RAPD typing of the R-plasmid-harboring isolates was done
according to the method described by Vogel et al.18 to
determine any predominant clone. Template DNA was pre-
pared from bacteria grown overnight at 37 8C on nutrient
agar plates. Crude DNA extracts were obtained by suspending
a colony in 50 ml of distilled water and boiling at 95 8C for
5 min. Each RAPD-PCR reaction consisted of Ready-To-Go PCR
bead (Amersham Biosciences, Amersham, UK), 25 pmol of
primer ERIC-2b, and 2 ml of DNA template in a final reaction
volume of 25 ml. The cycling conditions were as follows: one
cycle at 94 8C for 2 min; 35 cycles at 94 8C for 1 min, 25 8C for
1 min, and 72 8C for 4 min; and a final cycle at 94 8C for 1 min,
25 8C for 1 min, and 72 8C for 8 min. RAPD products were
separated on a 1.5% agarose gel containing ethidium bromide
(0.5 mg/l) with TAE running buffer. Molecular size marker
ladders (100-bp; Bioline, London, UK) were included on all
gels. Isolates of the same species were typed in the same
batch and products run on the same gel. Banding patterns
were evaluated using PhotoCaptMW software (Vilber Lour-
mat, USA). The whole RAPD experimentation was performed
in duplicate to look for any major differences in the banding
patterns of individual isolates.
Comparative analysis of ESBL detection by double
disk synergy test (DDST) and three-dimensional
test (TDT)
The method of Jarlier et al.,19 with some modifications, was
used for the detection of ESBL by DDST. Ceftazidime (30 mg)
and amoxicillin—clavulanate (20/10) were used. Taking into
consideration the controversies on optimal disk placement,
various modifications were tried, putting the CAZ and amox-
icillin—clavulanate disks at 5, 10, 15, 20, and 30 mm apart.
For determination of ESBL by TDT, the isolates were first
screened by spot-inoculation method,11 and then further
confirmed by the modified TDT as described previously.11
Results
Of the 2655 samples that were cultured, 528 (19.9%) yielded
bacterial growth, of which 139 (26.3%) bacterial isolates
were obtained from urine samples and 389 (73.7%) from
pus samples. The comparative results of the bacterial iso-
lates obtained from urine and pus samples are shown in
Figure 1. Only the E. coli (n = 181) and K. pneumoniae
(n = 61) isolates were included for further studies.
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Figure 1 Bacterial isolatesobtainedfromurineandpussamples.Antibiotic susceptibility
The results of the antibiotic susceptibility testing are shown
in Table 1. The isolates of E. coli obtained from urine samples
showedmaximum susceptibility to amikacin (57.1%) followed
by tobramycin (38.5%) and gentamicin (31.9%). Eighteen
(19.8%) isolates were susceptible to cefotaxime, whereas
11 (12.1%) were susceptible to ceftriaxone. The K. pneumo-
niae isolates from urine samples showed maximum suscept-
ibility to tobramycin (63.6%) followed by amikacin (54.5%).
Of the K. pneumoniae isolates, 31.8% were susceptible to
cefotaxime and 13.6% were susceptible to ceftriaxone. A
more or less similar trend of antibiotic susceptibility was
noticed in E. coli and K. pneumoniae isolates from pus
samples (Table 1).
Aminoglycoside resistance phenotypes and
possible resistance mechanisms
The aminoglycoside resistance phenotypes of E. coli obtained
from urine and pus samples are shown in Table 2. Of the E.
coli isolates from urine samples, themost common resistance
phenotype was GnNtTbAkKnNe, noted in 29 (31.9%) isolates
followed by Gn and GnNtTbKn(r)Ne, which were noted in 14
(15.4%) isolates of E. coli each.Table 1 Percent antibiotic susceptibility of Escherichia coli and
against the first-line antibiotics tested
Antibiotics Urine
E. coli (n = 91) K. pneumoniae (n
Ampicillin 3.3 (3) NT
Co-trimoxazole 11.0 (10) 4.5 (1)
Tetracycline 8.8 (8) 9.1 (2)
Ciprofloxacin 23.1 (21) 31.8 (7)
Gentamicin 31.9 (29) 45.5 (10)
Amikacin 57.1 (52) 54.5 (12)
Tobramycin 38.5 (35) 63.6 (14)
Cefotaxime 19.8 (18) 31.8 (7)
Ceftriaxone 12.1 (11) 13.6 (3)
Nitrofurantoin 11.0 (10) 9.1 (2)
Norfloxacin 23.1 (21) 31.8 (7)
Figures are % (number of isolates). The isolates were resistant to multInferring the resistance mechanism, the most common
resistance mechanism noted in 31.9% isolates was due to
impermeability. The most common aminoglycoside-modifying
enzymes inferred by interpretative reading were AAC(3)-I and
AAC(3)-IV, followed by AAC(60). However, 13 (14.3%) isolates
could not be characterized on the basis of interpretative
reading (Table 2). Among the E. coli isolates from pus samples,
again GnNtTbAkKnNe was found to be the most common
resistance phenotype in 27 (30%) isolates. The most common
aminoglycoside-modifying enzyme inferredwas AAC(3)-II in 10
(11.1%) isolates followed by AAC(3)-I and AAC(60) in nine (10%)
and eight (8.9%) isolates, respectively. Sixteen (17.8%) isolates
couldnot be characterized by interpretative reading (Table 2).
The aminoglycoside resistance phenotypes of K. pneumo-
niae obtained from urine and pus samples are given in
Table 3. Scattered frequencies of resistance phenotypes
were noted in isolates from urine samples and the most
common aminoglycoside-modifying enzymes inferred were
AAC(60) and ANT(20) noted in 13.6% isolates each. Among the
isolates from pus samples, the most common resistance
phenotype was GnNtTbAkKnNe, noted in 33.3% isolates,
and impermeability was inferred as the possible resistance
mechanism. The most common aminoglycoside-modifying
enzymes inferred by interpretative reading were APH(30)
and AAC(3)-II. However, 12.8% isolates could not be charac-
terized on the basis of interpretative reading (Table 3).
Cephalosporin resistance phenotypes and
possible resistance mechanisms
The cephalosporin resistance phenotypes of E. coli and K.
pneumoniae and their possible resistance mechanisms are
shown in Table 4. Fourteen (7.7%) E. coli isolates and six
(9.8%) K. pneumoniae could not be characterized by inter-
pretative reading because of complex resistance patterns
(i.e., simultaneous occurrence of ESBLs and AmpC enzymes
(Table 4)).
Occurrence of ESBL-producers
On the basis of NCCLS-ESBL phenotypic confirmatory test, 26
(14.4%) E. coli isolates and 15 (24.6%) K. pneumoniae wereKlebsiella pneumoniae isolates from urine and pus samples
Pus
= 22) E. coli (n = 90) K. pneumoniae (n = 39)
2.2 (2) NT
2.2 (2) 0 (0)
4.4 (4) 12.8 (5)
22.2 (20) 28.2 (11)
24.4 (22) 30.8 (12)
46.7 (42) 35.9 (14)
31.1 (28) 46.2 (18)
15.6 (14) 7.7 (3)
5.6 (5) 7.7 (3)
NT NT
NT NT
iple antibiotics. NT = not tested.
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Table 2 Aminoglycoside resistance phenotypes and mechanisms of resistance in Escherichia coli isolates
Resistance phenotypes Interpretation % Isolation from urine (n) % Isolation from pus (n)
GnNtTbAkKnNe Impermeability 31.9 (29) 30 (27)
Susceptible to all Classical 15.4 (14) 6.7 (6)
Gn AAC(3)-I 15.4 (14) 10 (9)
NtTbAkKnNe AAC(60) 6.6 (6) 8.9 (8)
KnNe APH(30) 1.1 (1) 2.2 (2)
GnNtTbKn(r)Ne AAC(3)-IV 15.4 (14) 5.6 (5)
GnNtTbKn(r) AAC(3)-II — 11.1 (10)
GnTbKn ANT(20) — 7.8 (7)
GnNtAkKnNe Unclassified 1 4.4 (4) —
NtAkKnNe Unclassified 2 1.1 (1) 4.4 (4)
TbKnNe Unclassified 3 8.8 (8) —
GnAk Unclassified 4 — 8.9 (8)
Tb Unclassified 5 — 4.4 (4)
Total — 100 (91) 100 (90)
Antibiotics: Gn = gentamicin, Nt = netilmicin, Tb = tobramycin, Ak = amikacin, Kn = kanamycin, Ne = neomycin. r = reduced zones but likely
to remain susceptible at British Society for Antimicrobial Chemotherapy (BSAC) breakpoints.
Table 3 Aminoglycoside resistance phenotypes and mechanisms of resistance in Klebsiella pneumoniae isolates
Resistance phenotypes Interpretation % Isolation from urine (n) % Isolation from pus (n)
GnNtTbAkKnNe Impermeability 18.2 (4) 33.3 (13)
Susceptible to all Classical 22.7 (5) 10.3 (4)
Gn AAC(3)-I 4.5 (1) 2.6 (1)
NtTbAkKnNe AAC(60) 13.6 (3) 7.7 (3)
KnNe APH(30) 9.1 (2) 12.8 (5)
GnNtTbKn(r) AAC(3)-II 4.5 (1) 12.8 (5)
GnKn ANT(20) 13.6 (3) 7.7 (3)
GnNtAkKn Unclassified 1 13.6 (3) —
GnAkKn Unclassified 2 — 12.8 (5)
Total — 100 (22) 100 (39)
Antibiotics: Gn = gentamicin, Nt = netilmicin, Tb = tobramycin, Ak = amikacin, Kn = kanamycin, Ne = neomycin. r = reduced zones but likely
to remain susceptible at British Society for Antimicrobial Chemotherapy (BSAC) breakpoints.found to be ESBL-producers (Table 4). Of the 26 isolates of E.
coli, nine (34.6%) were obtained from urine samples and 17
(65.4%) were from pus samples. Among the K. pneumoniae
isolates, four (26.7%) were from urine samples and 11 (73.3%)
were from pus samples.
Occurrence of AmpC enzymes
As there are no NCCLS phenotypic confirmatory criteria for
detection of AmpC b-lactamases, all the isolates of E. coli
and K. pneumoniae were tested by TDT for the presence of
AmpC b-lactamases. Eighteen (9.9%) isolates of E. coli and 19
(31.1%) isolates of K. pneumoniae were found to be AmpC
enzyme-producers by TDT (Table 4 and Figure 2). Most of the
isolates of E. coli and K. pneumoniae identified to be AmpC
producers by TDTeither did not have or had a very small zone
of inhibition ranging between 8 and 10 mm in diameter.
Comparing the cefoxitin zone diameters of the isolates with
TDT-positivity, all but one isolate had zone diameter lower
than the cut-off criterion, i.e., 18 mm zone diameter. One
isolate of E. coli had a zone diameter of 22 mm.Simultaneous occurrence of ESBLs and AmpC
enzymes
Simultaneous occurrence of ESBLs and AmpC enzymes were
noted in 14 isolates of E. coli (7.7%) and six isolates of K.
pneumoniae (9.8%) (Table 4). All the isolates were obtained
from pus samples. These 20 isolates were further selected for
plasmid screening, curing, and transconjugation experi-
ments, RAPD-PCR typing, and comparative analysis of ESBL
detection by DDST and TDT.
Plasmid analysis, plasmid curing, and
transconjugation experiments
All the isolates of E. coli and K. pneumoniae selected for
plasmid analysis were found to harbor a single plasmid of
19.9 kb (Figure 3). Curing and transconjugation experiments
were attempted in these isolates to determine the change in
plasmid content associated with the antibiotic resistance
pattern. The MICs of the ethidium bromide ranged between
400 and 600 mg/ml for these isolates. The loss of antibiotic
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Table 4 Occurrence of b-lactamase and cephalosporin resistance phenotypes and mechanisms of resistance in Escherichia coli
and Klebsiella pneumoniae isolates
b-Lactamases % Positivity (n) Resistance phenotypes (n) Resistance
mechanisma
Total
(242)
E. coli
(181)
K. pneumoniae
(61)
E. coli K. pneumoniae
ESBL alone 8.7 (21) 6.6 (12) 14.8 (9) AmAx/ClTiTi/ClPiPi/
TzCfCzCtCpAz (6)
— ESBL-broad
AmTiPiPi/TzCfCzCtCpAz (1) — ESBL-broad
AmTiPiPi/TzCfCzCt(r)
Cp(r)Az(r) (3)
— ESBL-ceftazidimase
AmTiPiCfCzCt(r)
Cp(r)Az(r) (2)
— ESBL-ceftazidimase
— AmAx/ClTiTi/ClPiPi/
TzCfCzCtCpAz (5)
ESBL-broad
— AmTiPiPi/TzCfCzCtCpAz (2) ESBL-broad
— AmTiPiPiTzCfCzCt(r)
Cp(r)Az(r) (2)
ESBL-ceftazidimase
AmpC
alone
7.0 (17) 2.2 (4) 21.3 (13) AmAx/ClTiTi/ClPiPi/
TzCfCxCzCtAz (4)
— AmpC high
— AmAx/ClTiTi/ClPiPi/
TzCfCxCzCtAz (13)
AmpC acquired
AmpC +
ESBL
8.3 (20) 7.7 (14) 9.8 (6) AmAx/ClTiTi/ClPiPi/
TzCfCxCzCtCpAz (14)
AmAx/ClTiTi/ClPiPi/
TzCfCxCzCtCpAz (6)
Unclassified by
interpretative
reading
Antibiotics: Am = ampicillin, Ax/Cl = amoxicillin—clavulanate, Ti = ticarcillin, Ti/Cl = ticarcillin—clavulanate, Pi = piperacillin, Pi/Tz = pi-
peracillin—tazobactam, Cf = cephalothin, Cx = cefoxitin, Cz = ceftazidime, Ct = ceftriaxone, Cp = cefepime, Az = aztreonam. r = reduced
zones but likely to remain susceptible at British Society for Antimicrobial Chemotherapy (BSAC) breakpoints.
a Inferred according to interpretative reading (see Ref. 15). Figures in parentheses indicate number of isolates.resistance was concomitant with the loss of plasmid content.
It was noted that all the K. pneumoniae isolates that lost
plasmids became susceptible to cefoxitin and tetracycline,
while remaining resistant to cephalosporins (not giving any
zone of inhibition to cephalosporins after curing experi-
ments) and other antibiotics. Among the E. coli isolates,Figure 2 Three-dimensional test (TDT) for detection of b-lactama
for detection of ESBLs and cefoxitin (30 mg) was used for AmpC dete
flattening (small arrow) or clear distortion (large arrow) were taken a
arrow) were taken as ESBL/AmpC non-producers. (b) Modified thre
distortion (large arrow) show ESBL/AmpC producers and no distorti10 (71.4%) became susceptible to cefoxitin and tetracycline
while remaining resistant to cephalosporins and other anti-
biotics, and did not gave any zone of inhibition to these
antibiotics. However, four (28.6%) isolates revealed cepha-
losporin zone diameters ranging between 10 and 16 mm, in
addition to susceptibility to cefoxitin and tetracycline. Afterses (ESBLs and AmpC type). Ceftazidime disks (30 mg) were used
ction. (a) Spot-inoculation method. The isolates showing either
s ESBL/AmpC producers. The isolates with no distortion (medium
e-dimensional extract test. Flattening (small arrow) and clear
on (medium arrow) shows non-producers.
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Figure 3 Agarose gel (0.8%) showing 19.9-kb plasmids. Mole-
cular weight markers along with their sizes (in kb pairs) are
shown on the extreme left.repeated attempts, all the isolates subjected to transconju-
gation experiments were able to transfer resistance to cefox-
itin and tetracycline. Plasmid analysis of the transconjugants
revealed the presence of a similar 19.9-kb plasmid.
RAPD analysis
The isolates could not be grouped into clusters because of
unique banding patterns (see Figure 4). No gross banding
difference was noticed between two RAPD-PCR experiments.
Comparison between DDST and TDT
ESBLs were detected in three (15%) isolates by DDST in the
experiments where ceftazidime and amoxicillin—clavulanate
disks were placed 5 mm apart. The rest of the experiments
with disks placement at 10, 15, 20, and 30 mm did notFigure 4 Agarose gel (1.5%) showing the RAPD profiles of the
Escherichia coli isolates. Lanes 1, 10, and 20 have molecular
weight markers. Lanes 11 and 12 show the RAPD pattern of a
single E. coli isolate, in duplicate experiments demonstrating no
significant difference.demonstrate the presence of ESBLs. On the other hand, ESBLs
were detected in 16 (80%) isolates by TDT.
Discussion
The increase in multidrug-resistant strains of E. coli and K.
pneumoniae producing the ESBLs and AmpC enzymes has
limited therapeutic options.6,20 Therefore, early identifica-
tion of infections due to these organisms is necessary as
prompt institution of appropriate treatment might reduce
the mortality in hospitalized patients.21,22 In our study,
markedly high resistance to cephalosporins and aminoglyco-
sides was noticed in clinical isolates of E. coli and K. pneu-
moniae. Compared with earlier reports that have examined
the susceptibility to various antibiotics of E. coli and K.
pneumoniae,23 there is a clear tendency towards decreased
susceptibility for all groups of antibiotics.
Impermeability was inferred to be the most common
aminoglycoside resistance mechanism in our E. coli and K.
pneumoniae isolates. AAC(3)-I was the most common ami-
noglycoside-modifying enzyme inferred in 23 (12.7%) isolates
of E. coli. However scattered frequencies of resistance phe-
notypes were inferred in K. pneumoniae isolates, and APH(30)
was inferred to be the most common aminoglycoside-mod-
ifying enzyme. Regarding the cephalosporin/cephamycin
resistance mechanisms, production of ESBL was noticed in
16.9% of isolates, whereas the production of AmpC enzyme
was noted in 15.3% of isolates. It must be emphasized here
that simultaneous occurrence of AmpC and ESBL was noticed
in 8.3% of isolates, in which the mechanism could not be
inferred by interpretative reading. This is the first report
from India regarding the aminoglycoside/cephalosporin
resistance mechanisms, and our results could not be com-
pared to others due to the paucity of Indian studies on this
subject.
ESBLs are widespread all over the world, but the preva-
lence and phenotypic characteristics among clinical isolates
may vary between geographical areas.24,25 In the present
study, we noticed the occurrence of ESBLs in 14.3% E. coli
isolates and 24.5% of K. pneumoniae by NCCLS phenotypic
test, and this is in concordance with earlier published
reports.23,24 AmpC enzymes were noticed in 9.9% E. coli
and 31.1% K. pneumoniae isolates in our study. The preva-
lence of AmpC b-lactamases in this study is significantly high
as compared to that found in earlier reported studies from
other countries,26,27 however it is in agreement with the
prevalence found in a few reports published from India.28 It is
interesting to note that the simultaneous occurrence of ESBLs
and AmpC enzymes was found in a fair percentage of isolates
(7.7% and 9.8% isolates of E. coli and K. pneumoniae, respec-
tively). This is among the first reports demonstrating a high
frequency of simultaneous occurrence of ESBL and AmpC
enzymes in E. coli and K. pneumoniae isolates, particularly
one of the first from India.
The acquisition of AmpC-type genes by plasmids in E. coli
and K. pneumoniae has been known of since the 1980s.4
However studies regarding plasmid-mediated AmpC b-lacta-
mases are rudimentary in our country. In this study, we found
that the cause of cefoxitin resistance in E. coli and K.
pneumoniae isolates from our hospital is the acquisition of
a similar self-transmissible plasmid of 19.9 kb. Observing the
similar plasmids in different isolates, we attempted to look
Antibiotic resistance in an Indian tertiary care hospital 263for any predominant clone that exists in our bacterial popu-
lation by RAPD-PCR typing. No predominant clone was iden-
tified, indicating horizontal transfer of the 19.9 kb plasmids
between unrelated strains as well as widespread dissemina-
tion between the genera (Escherichia and Klebsiella).
Gazouli et al.29 have also reported that E. coli and K.
pneumoniae isolates from a Greek hospital acquired cefoxitin
resistance due to the acquisition of a plasmid of 8.3 kb.
In summary, the prevalence of multidrug-resistant bac-
terial isolates is quite high in our locality. The prevalence of
ESBLs by phenotypic NCCLS criteria was found to be 14.3% in
E. coli isolates and 24.5% in K. pneumoniae isolates, and the
prevalence of AmpC enzymes by phenotypic detection (TDT)
was found to be 9.9% in E. coli isolates and 31.1% in K.
pneumoniae isolates. Combinations of aminoglycoside-
modifying enzymes were found responsible for aminoglyco-
side resistance, whereas the most common inferred cepha-
losporin resistance phenotypes were ‘ESBL-broad’. The
modified TDT was found to be the better method for ESBL
detection as compared to the DDST, especially in isolates
not giving any zone of inhibition to cephalosporins where we
could not judge the optimal placement of cephalosporin and
amoxicillin—clavulanate disks. A 19.9-kb plasmid was con-
sistently present in all the isolates of E. coli and K. pneu-
moniae that were inferred to encode cefoxitin resistance
based on curing and transconjugation experiments. RAPD
analysis shows that no predominant clone exists; the
bacterial population is rather diverse and horizontal
transfer of the plasmids has occurred between unrelated
strains.
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